Perspective Therapeutics (CATX)
:CATX
Top Page
Perspective Therapeutics
(CATX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$4.00
▼(-8.05% Downside)
Action:ReiteratedDate:04/02/26
The score is held down primarily by weak financial performance (no current revenue, widening losses, and rising cash burn). Technical indicators also point to soft momentum. These negatives are partially offset by positive pipeline/manufacturing updates and strengthened funding from recent capital raises.
Positive Factors
Clinical-stage efficacy and tolerability (VMT-α-NET)
Robust early efficacy and a favorable safety profile in the lead VMT-α-NET program materially improve the program's probability of advancing into registrational discussions. Durable responses and tolerability reduce clinical development risk and support longer-term commercial potential for a first-in-class radiopharmaceutical.
Negative Factors
No current revenue and widening net losses
Being pre-revenue with materially widening losses is a persistent structural headwind: the company lacks product cash flow, must rely on external capital, and faces long lead times to commercialization. Sustained losses compress financial flexibility and raise execution and funding risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical-stage efficacy and tolerability (VMT-α-NET)
Robust early efficacy and a favorable safety profile in the lead VMT-α-NET program materially improve the program's probability of advancing into registrational discussions. Durable responses and tolerability reduce clinical development risk and support longer-term commercial potential for a first-in-class radiopharmaceutical.
Read all positive factors
Perspective Therapeutics (CATX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$509.28M
Dividend YieldN/A
Average Volume (3M)1.53M
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees138
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.51
Shares Outstanding113,933,430
10 Day Avg. Volume952,717
30 Day Avg. Volume1,532,342
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue346.55
Enterprise Value/Gross Profit-208.33
Enterprise Value/Ebitda-4.70
Forecast
1Y Price Target
$12.64Price Target Upside190.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.16
Revenue Forecast (FY)$687.43K
Perspective Therapeutics Business Overview & Revenue Model
Company Description
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally...
How the Company Makes Money
As a clinical-stage company, Perspective Therapeutics’ business model is primarily R&D-driven rather than based on recurring commercial product sales. Revenue, when present, typically comes from non-product sources such as collaboration/licensing ...
Perspective Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 1.43M | 7.10M | 10.79M |
| Gross Profit | 0.00 | 0.00 | 1.43M | 1.63M | 4.62M |
| EBITDA | 9.14M | 10.46M | -39.96M | -14.84M | -7.39M |
| Net Income | -103.12M | -79.28M | -46.51M | -14.67M | -7.15M |
Balance Sheet | |||||
| Total Assets | 266.97M | 341.10M | 97.89M | 58.09M | 67.25M |
| Cash, Cash Equivalents and Short-Term Investments | 144.74M | 226.92M | 9.24M | 43.76M | 60.35M |
| Total Debt | 1.63M | 4.06M | 2.55M | 0.00 | 652.00K |
| Total Liabilities | 59.94M | 50.43M | 22.71M | 3.45M | 2.86M |
| Stockholders Equity | 207.03M | 290.67M | 75.18M | 54.64M | 64.39M |
Cash Flow | |||||
| Free Cash Flow | -95.23M | -72.71M | -37.98M | -12.47M | -7.98M |
| Operating Cash Flow | -82.48M | -18.29M | -36.91M | -12.17M | -7.71M |
| Investing Cash Flow | 41.23M | -218.93M | 24.37M | -57.68M | -284.00K |
| Financing Cash Flow | 10.30M | 289.38M | 785.00K | 56.00K | 56.00K |
Perspective Therapeutics Technical Analysis
Positive
4.35
Price Trends
4.82
Negative
3.68
Positive
3.60
Positive
Market Momentum
-0.10
Negative
48.73
Neutral
79.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CATX, the sentiment is Positive. The current price of 4.35 is below the 20-day moving average (MA) of 4.47, below the 50-day MA of 4.82, and above the 200-day MA of 3.60, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 48.73 is Neutral, neither overbought nor oversold. The STOCH value of 79.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CATX.
Perspective Therapeutics Risk Analysis
Perspective Therapeutics disclosed 55 risk factors in its most recent earnings report. Perspective Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We may not be successful in managing the build-out of our manufacturing facilities and associated costs or satisfying manufacturing-related regulatory requirements. Q3, 2024
Perspective Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $367.11M | 19.35 | 10.87% | ― | 18.90% | 29.22% | |
76 Outperform | $199.60M | 21.81 | 20.28% | ― | 16.05% | 29.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $509.28M | -1.35 | -41.27% | ― | ― | ― | |
50 Neutral | $258.71M | -6.74 | 137.18% | ― | 49.52% | 19.34% | |
47 Neutral | $157.72M | -2.53 | -29.28% | ― | -2.69% | -149.18% | |
47 Neutral | $144.74M | -4.35 | -32.46% | ― | 15.19% | -3.32% |
* Healthcare Sector Average
CATX
Perspective Therapeutics
4.35
2.30
112.20%
ELMD
Electromed
24.95
1.93
8.38%
QTRX
Quanterix
3.39
-2.21
-39.46%
VMD
Viemed Healthcare
9.69
3.10
47.04%
NNOX
Nano-X Imaging
2.38
-2.36
-49.79%
TLSI
TriSalus Life Sciences
4.35
-1.20
-21.62%
Perspective Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics Highlights Progress in 212Pb Oncology Pipeline
Positive
Apr 1, 2026
On April 1, 2026, Perspective Therapeutics updated its corporate presentation to highlight progress across its wholly owned 212Pb-based oncology portfolio, emphasizing its strategy to redefine radiotherapy in solid tumors. The company underscored ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Perspective Therapeutics Reports 2025 Results, Highlights Pipeline Progress
Positive
Mar 16, 2026
On March 16, 2026, Perspective Therapeutics reported full-year 2025 results and recent business highlights, underscoring progress across all three clinical-stage radiopharmaceutical programs and strengthening its financial position. Updated data f...
Business Operations and StrategyPrivate Placements and Financing
Perspective Therapeutics Raises Capital to Advance Radiopharmaceutical Pipeline
Positive
Feb 3, 2026
On February 2, 2026, Perspective Therapeutics, Inc. entered into an underwriting agreement for a previously announced underwritten offering of 39,576,088 common shares and pre-funded warrants to purchase 6,598,046 shares, priced at $3.79 per share...
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics Highlights Progress in Radiopharmaceutical Pipeline
Positive
Feb 2, 2026
On February 2, 2026, Perspective Therapeutics posted an investor presentation outlining progress across its pipeline of 212Pb-based radiopharmaceutical therapies and its broader strategy in oncology. The company highlighted ongoing Phase 1/2a clin...
Business Operations and StrategyProduct-Related Announcements
Perspective Therapeutics Highlights Progress in Radioligand Oncology Pipeline
Positive
Jan 14, 2026
On January 14, 2026, Perspective Therapeutics updated its corporate presentation to highlight progress on its 212Pb-based radioligand platform and expanding oncology pipeline. The company detailed three ongoing Phase 1/2a clinical programs—V...
Business Operations and Strategy
Perspective Therapeutics outlines 2026 clinical and manufacturing priorities
Positive
Jan 12, 2026
On January 12, 2026, Perspective Therapeutics announced business updates and strategic priorities for the next 12–18 months, highlighting steady clinical progress across its pipeline and moves to scale manufacturing ahead of broader data rea...
Business Operations and Strategy
Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data
Positive
Jan 9, 2026
On January 9, 2026, Perspective Therapeutics reported updated interim data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2‑expressing neuroendocrine tumors, based on a December 10,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.